# Phase 2 Study in Patients With MiT Tumors

> **NCT00557609** · PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 47 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Alveolar Soft Part Sarcoma (ASPS)
- Clear Cell Sarcoma (CCS)

## Interventions

- **DRUG:** ARQ 197

## Key facts

- **NCT ID:** NCT00557609
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-12
- **Final completion:** 2011-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00557609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00557609, "Phase 2 Study in Patients With MiT Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00557609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*